Ignite Creation Date:
2025-12-24 @ 9:10 PM
Ignite Modification Date:
2026-01-05 @ 5:09 PM
Study NCT ID:
NCT00243204
Status:
TERMINATED
Last Update Posted:
2007-06-08
First Post:
2005-10-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
Sponsor:
Point Therapeutics
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-01
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2005-10-19
First Submit QC Date:
None
Study First Post Date:
2005-10-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2007-06-07
Last Update Post Date:
2007-06-08
Last Update Post Date Type:
ESTIMATED